Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Apr;10(6):331-5.
doi: 10.1016/j.autrev.2010.12.002. Epub 2010 Dec 15.

Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis

Weihong Liu  1 , Bo Peng, Yumin Lu, Weijia Xu, Wei Qian, Jian-Ying Zhang
Affiliations
Review

Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis

Weihong Liu et al. Autoimmun Rev. 2011 Apr.

Abstract

Cancer sera contain antibodies that react with a unique group of autologous cellular antigens called tumor-associated antigens (TAAs), and therefore these autoantibodies can be considered as reporters from the immune system, to identify authentic TAAs involved in the malignant transformation. Once a TAA is identified, different approaches would be used to comprehensively characterize and validate the identified TAA/anti-TAA systems that are potential biomarkers in cancer immunodiagnosis. In this manner, several novel TAAs such as p62 and p90 have been identified in our previous studies. p62, a member of IGF-II mRNA binding proteins (IMPs), is an oncofetal protein absent in adult tissues, the presence of anti-p62 autoantibodies relates to abnormal expression of p62 in tumor cells. p90 was recently characterized as an inhibitor of the tumor suppressor PP2A (protein phosphatase 2A), and an autoantibody to p90 appears in high frequency in prostate cancer. The present review will focus on the recent advances in studies mainly associated with these two novel TAAs as biomarkers in cancer immunodiagnosis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Reactivity of three HCC sera in Western blotting against whole cell extracts from MOLT-4, T24, and HepG2 cell lines. Lanes 1, 5, and 9 were normal human sera. One HCC serum (lanes 2, 6, and 10) showed strong reactivity with a 90-kDa protein in MOLT-4 cells and reacted weakly with a 62-kDa protein in MOLT-4 cells and T24 cell extracts. A strong reaction with the 62-kDa protein was detected with HepG2 cell extracts, together with a strong reaction with a 50-kDa protein. The second serum (lanes 3, 7, and 11) and the third one (lanes 4, 8, and 12) demonstrate other types of reactions. These representative data demonstrate that HCC sera are heterogeneous in their antibody repertoires and that different cell lines apparently have different expressions of 90-, 62-, and 50-kDa proteins.
See this image and copyright information in PMC

References

    1. Tan EM. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest. 2001;108(10):1411–5. - PMC - PubMed
    1. Old LJ, Chen YT. New paths in human cancer serology. J Exp Med. 1998;187(8):1163–7. - PMC - PubMed
    1. Tan EM, Zhang J. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev. 2008;222:328–40. - PMC - PubMed
    1. Anderson KS, LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res. 2005;4(4):1123–33. - PMC - PubMed
    1. Imai H, Ochs RL, Kiyosawa K, Furuta S, Nakamura RL, Tan EM. Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Path. 1992;140(4):859–70. - PMC - PubMed

Publication types